Hims & Hers (HIMS) stock is down ~40% YTD but remains a "Buy." Learn why compressed valuation and Eucalyptus-led Europe/Japan ...

Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 9, Novo Nordisk A/S (NYSE:NVO) announced its partnership with Hims & Hers. The deal ...

Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill Based on an independent provider’s clinical decision, ...

Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is ...

Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill Starting today, eligible customers can access a broad ...

Hims & Hers (HIMS) stock fell 39% in 2026 after shifting to branded GLP-1 drugs. Amazon's Foundayo launch adds pressure.

Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill Hims & Hers Health, Inc. (NYSE: HIMS) today announced that ...

Hims & Hers (HIMS) has taken a beating, with the stock down roughly 70% from its $70 peak and now trading below $21 per share. But the story's changing. After the company's Novo Nordisk (NVO) deal and ...

The recent deal between Novo Nordisk and Hims & Hers is already resulting in new product announcements for Hims & Hers. The fastest GLP-1 launch in history could be boosted by a wider distribution ...